Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Abstract Text:

Efdal Yoeruek,Herbert ,Matthias ,Salvatore Grisanti,Max Warga,Ralf Krott,Martin Stephan Spitzer,Olcay Tatar,Karl Ulrich Bartz-Schmidt,Peter Szurman,Efdal Yoeruek,Herbert ,Matthias ,Salvatore Grisanti,Max Warga,Ralf Krott,Martin Stephan Spitzer,Olcay Tatar,Karl Ulrich Bartz-Schmidt,Peter Szurman,

PURPOSE: To evaluate the clinical safety of a taurine containing irrigation solution (AcriProTect) before its routine application in pars plana vitrectomy (PPV). METHODS: Twenty-five patients who underwent PPV were included in this prospective interventional clinical study. Standard irrigation solution containing the addendum 3 mmol/L taurine was used during PPV. Postoperative follow-up visits included a standard eye examination, corneal thickness measurements, endothelial cell counts, determination of the foveal thickness by optical coherence tomography (OCT), and an electrophysiologic examination. For statistical analysis Wilcoxon test was used. RESULTS: Significant improvement of visual acuity (VA) was observed at the 3- and 6-month controls (P = 0.024; P = 0.002 for 3 and 6 months, respectively). Endothelial cell counts and corneal thickness at 3 and 6 months were not significantly different from preoperative values (P = 0.204; P = 0.126 for endothelial cell count and P = 0.475; P = 0.095 for corneal thickness at 3 and 6 months, respectively). Both scotopic and photopic Ganzfeld electroretinography and electro-oculography did not show significant changes during the follow-up. No increase in complication rate was detected. CONCLUSIONS: The investigation demonstrates a good biocompatibility of taurine-containing irrigation solution developed for vitrectomy in humans concomitant with habitually observed good functional outcome.

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Publishing Authors By Initials

E Yoeruek,H ,M ,S Grisanti,M Warga,R Krott,MS Spitzer,O Tatar,KU Bartz-Schmidt,P Szurman,E Yoeruek,H ,M ,S Grisanti,M Warga,R Krott,MS Spitzer,O Tatar,KU Bartz-Schmidt,P Szurman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2007 Nov-Dec

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Retina (Philadelphia, Pa.)

VOLUME: 27

Page Numbers: 1286-91

Journal Abbreviation: Retina (Philadelphia, Pa.)

ISSN: 0275-004X

DAY: 29

MONTH: 11

YEAR: 2007

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309919

Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.

AFFILIATION: Department of Ophthalmology, University of Tuebingen, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Retina

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety profile of a taurine containing irrigation solution AcriProTect in pars plana vitrectomy Related Publications

• August consultation #4.
• Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
• Effects of bevacizumab on retinal function in isolated vertebrate retina.
• Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
• Electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina.
• Safety profile of a taurine containing irrigation solution (AcriProTect) in pars plana vitrectomy.
• Safety profile of bevacizumab on cultured human corneal cells.
• Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
• Suppression of melanoma-associated neoangiogenesis by bevacizumab.
• The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina.
• Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells.
• [Optic atrophy subsequent to epiretinal triamcinolone deposits in an eye following inner limiting membrane peeling.]